Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Taurursodiol

FDA-approved product (for suspension, oral).

Registered studies
43
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Taurursodiol
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Taurursodiol. Its therapeutic class is shown instead.

WHO therapeutic group
Bile acids and derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA79.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli17.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

43registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Taurursodiol in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Taurursodiol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes

    NCT02218619 · start 2015-08

    Registered record
    Registry ID
    NCT02218619
    Conditions
    Type 1 Diabetes
    Interventions
    Tauroursodeoxycholic Acid (TUDCA); Sugar Pill (placebo)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-08
    Completion
    2019-12-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 1 Diabetes
    InterventionTauroursodeoxycholic Acid (TUDCA); Sugar Pill (placebo)
    PhasePhase 2
    Registry statusCompleted

  • Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance

    NCT01877551 · start 2013-09

    Registered record
    Registry ID
    NCT01877551
    Conditions
    HIV Related Insulin Resistance; Protease Inhibitor Related Insulin Resistance; Endoplasmic Reticulum Stress
    Interventions
    Tauroursodeoxycholic acid; Placebo tablet
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-09
    Completion
    2018-05
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Related Insulin Resistance; Protease Inhibitor Related Insulin Resistance; Endoplasmic Reticulum Stress
    InterventionTauroursodeoxycholic acid; Placebo tablet
    PhaseNot applicable
    Registry statusCompleted

  • Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy

    NCT01855360 · start 2013-06

    Registered record
    Registry ID
    NCT01855360
    Conditions
    Amyloidosis; Heart (Manifestation); Senile Cardiac Amyloidosis
    Interventions
    Tauroursodeoxycholic Acid and Doxycycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2013-06
    Completion
    2015-05-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyloidosis; Heart (Manifestation); Senile Cardiac Amyloidosis
    InterventionTauroursodeoxycholic Acid and Doxycycline
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • The Discovery of the Double Sphincter in Gallbladder

    NCT01998451 · start 2012-12

    Registered record
    Registry ID
    NCT01998451
    Conditions
    Gallstone
    Interventions
    Tauroursodeoxycholic acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2012-12
    Completion
    2018-12
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGallstone
    InterventionTauroursodeoxycholic acid
    PhasePhase 4
    Registry statusUnknown

  • Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis

    NCT01171859 · start 2010-07

    Registered record
    Registry ID
    NCT01171859
    Conditions
    Transthyretin Amyloidosis
    Interventions
    Doxycycline + Tauroursodeoxycholic acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-07
    Completion
    2015-10
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransthyretin Amyloidosis
    InterventionDoxycycline + Tauroursodeoxycholic acid
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis

    NCT01857284 · start 2009-09

    Registered record
    Registry ID
    NCT01857284
    Conditions
    Primary Biliary Cirrhosis
    Interventions
    Tauroursodeoxycholic Acid Capsules; Ursodeoxycholic Acid Capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-09
    Completion
    2013-01
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Biliary Cirrhosis
    InterventionTauroursodeoxycholic Acid Capsules; Ursodeoxycholic Acid Capsules
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety Study of TUDCA Compare UDCA to Treatment Chronic Cholestatic Liver Disease-PBC

    NCT01829698 · start 2009-08

    Registered record
    Registry ID
    NCT01829698
    Conditions
    Cholestatic Liver Disease
    Interventions
    tauroursodeoxycholic; ursodeoxycholic acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-08
    Completion
    2014-02
    Enrolment
    199

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCholestatic Liver Disease
    Interventiontauroursodeoxycholic; ursodeoxycholic acid
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis

    NCT00877604 · start 2008-06

    Registered record
    Registry ID
    NCT00877604
    Conditions
    Amyotrophic Lateral Sclerosis
    Interventions
    tauroursodeoxycholic acid (TUDCA); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-06
    Completion
    2012-04
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyotrophic Lateral Sclerosis
    Interventiontauroursodeoxycholic acid (TUDCA); Placebo
    PhasePhase 2
    Registry statusCompleted

  • Effect of Endoplasmic Reticulum Stress on Metabolic Function

    NCT00771901 · start 2008-02

    Registered record
    Registry ID
    NCT00771901
    Conditions
    Insulin Resistance; Diabetes; Obesity
    Interventions
    tauroursodeoxycholic acid; placebo; sodium phenylbutyrate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-02
    Completion
    2014-12
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsulin Resistance; Diabetes; Obesity
    Interventiontauroursodeoxycholic acid; placebo; sodium phenylbutyrate
    PhaseNot applicable
    Registry statusCompleted

  • Ursodiol in Huntington's Disease

    NCT00514774 · start 2007-08

    Registered record
    Registry ID
    NCT00514774
    Conditions
    Huntington Disease
    Interventions
    ursodiol; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2007-08
    Completion
    2009-06
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuntington Disease
    Interventionursodiol; placebo
    PhasePhase 1
    Registry statusUnknown

  • Randomized Study of Tauroursodeoxycholic Acid in Prophylactic Therapy of Total Parenteral Nutrition Associated Cholestasis in Infants

    NCT00004410 · start 1998-06

    Registered record
    Registry ID
    NCT00004410
    Conditions
    Cholestasis
    Interventions
    tauroursodeoxycholic acid
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1998-06
    Completion
    2002-03
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCholestasis
    Interventiontauroursodeoxycholic acid
    PhaseNot applicable
    Registry statusCompleted

  • Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis

    NCT00004441 · start 1997-09

    Registered record
    Registry ID
    NCT00004441
    Conditions
    Cystic Fibrosis
    Interventions
    tauroursodeoxycholic acid; ursodiol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1997-09
    Completion
    2001-09
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    Interventiontauroursodeoxycholic acid; ursodiol
    PhaseNot applicable
    Registry statusCompleted

  • An Intermediate Size Expanded Access Protocol of AMX0035 for ALS

    NCT05286372

    Registered record
    Registry ID
    NCT05286372
    Conditions
    Amyotrophic Lateral Sclerosis
    Interventions
    AMX0035
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Approved for marketing
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyotrophic Lateral Sclerosis
    InterventionAMX0035
    PhaseNot recorded
    Registry statusApproved for marketing